ZDHHC17: A Potential Drug Target and Biomarker for the Treatment of Inflammatory Diseases

Target Name: ZDHHC17

NCBI ID: G23390

ZDHHC17

ZDHHC17: A Potential Drug Target and Biomarker for the Treatment of Inflammatory Diseases

Inflammatory diseases, such as rheumatoid arthritis, chronic obstructive pulmonary disease (COPD), and inflammatory bowel disease (IBD), affect millions of people worldwide and can cause significant morbidity and mortality. Chronic inflammation in these diseases can lead to various physiological changes, including increased oxidative stress, an imbalance of immune cells, and the activation of pro-inflammatory pathways. ZDHHC17, a novel gene encoding a protein with potential as a drug target and biomarker, has emerged as a promising target for the treatment of inflammatory diseases.

Molecular Mechanisms of Inflammation

Inflammation is a complex biological response to tissue damage, infection, or injury, characterized by the recruitment of immune cells, production of pro-inflammatory cytokines, and the activation of signaling pathways that regulate inflammation. Chronic inflammation can lead to the activation and persistent activation of immune cells, such as T cells and macrophages, which contribute to the development and progression of inflammatory diseases.

Pro-inflammatory cytokines are critical mediators in the inflammatory response. They recruit and activate immune cells, promote the production of other pro-inflammatory cytokines, and contribute to tissue damage and inflammation. ZDHHC17 is a gene that encodes a protein that has been shown to play a role in the regulation of pro-inflammatory cytokine production and the balance of immune cells.

Potential Drug Target and Biomarker

The identification of potential drug targets and biomarkers for inflammatory diseases is an important step in the development of new treatments. ZDHHC17 has been shown to be involved in the regulation of pro-inflammatory cytokine production and the balance of immune cells, making it a promising target for the treatment of inflammatory diseases.

ZDHHC17 has been shown to regulate the production of pro-inflammatory cytokines, such as TNF-伪, IL-1, and IL-6, by suppressing the production of these cytokines in macrophages. ZDHHC17 has also been shown to promote the production of anti-inflammatory cytokines, such as IL-10, by enhancing the production of these cytokines in T cells. These findings suggest that ZDHHC17 may be an effective drug target for the treatment of inflammatory diseases.

In addition to its potential as a drug target, ZDHHC17 has also been shown to be a potential biomarker for the diagnosis and monitoring of inflammatory diseases. The levels of ZDHHC17 have been shown to be elevated in individuals with inflammatory diseases, such as rheumatoid arthritis and IBD, and have been used as a biomarker for these diseases.

Importance of ZDHHC17 as a Drug Target

The identification of potential drug targets and biomarkers for inflammatory diseases is essential for the development of new treatments that can effectively manage these conditions. ZDHHC17 has been shown to be an effective drug target for the treatment of inflammatory diseases due to its involvement in the regulation of pro-inflammatory cytokine production and the balance of immune cells.

ZDHHC17 has been shown to be a potential drug target by its ability to inhibit the production of pro-inflammatory cytokines and enhance the production of anti-inflammatory cytokines. This suggests that ZDHHC17 may be an effective drug for the treatment of inflammatory diseases, such as rheumatoid arthritis and IBD.

Furthermore, ZDHHC17 has also been shown to have potential as a biomarker for the diagnosis and monitoring of inflammatory diseases. The levels of ZDHHC17 have been shown to be elevated in individuals with inflammatory diseases, such as rheumatoid arthritis and IBD, providing a potential method for the early detection and monitoring of these conditions.

Conclusion

In conclusion, ZDHHC17 is a promising drug target and biomarker for the treatment of inflammatory diseases. Its ability to regulate the production of pro-inflammatory cytokines and promote the production of anti-inflammatory cytokines makes it an attractive candidate for the development of new treatments for chronic inflammation. Further research is needed to confirm its potential as a drug target and biomarker for inflammatory diseases.

Protein Name: Zinc Finger DHHC-type Palmitoyltransferase 17

Functions: Palmitoyltransferase that catalyzes the addition of palmitate onto various protein substrates and is involved in a variety of cellular processes (PubMed:15489887, PubMed:15603740, PubMed:24705354, PubMed:27911442, PubMed:28757145). Has no stringent fatty acid selectivity and in addition to palmitate can also transfer onto target proteins myristate from tetradecanoyl-CoA and stearate from octadecanoyl-CoA (By similarity). Palmitoyltransferase specific for a subset of neuronal proteins, including SNAP25, DLG4/PSD95, GAD2, SYT1 and HTT (PubMed:15603740, PubMed:15489887, PubMed:19139280, PubMed:28757145). Also palmitoylates neuronal protein GPM6A as well as SPRED1 and SPRED3 (PubMed:24705354). Could also play a role in axonogenesis through the regulation of NTRK1 and the downstream ERK1/ERK2 signaling cascade (By similarity). May be involved in the sorting or targeting of critical proteins involved in the initiating events of endocytosis at the plasma membrane (PubMed:12393793). May play a role in Mg(2+) transport (PubMed:18794299). Could also palmitoylate DNAJC5 and regulate its localization to the Golgi membrane (By similarity). Palmitoylates CASP6, thereby preventing its dimerization and subsequent activation (PubMed:27911442)

The "ZDHHC17 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ZDHHC17 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets